Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 70518-4491

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 70518-4491). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Lurasidone Hydrochloride 40 mg film-coated tablets packaging label showing a quantity of 30 tablets. The label indicates the product is repackaged by RemedyRepack Inc., Indiana, PA, with storage instructions and a reminder to keep medication out of reach of children. The label includes lot, expiration, and NDC details, and the tablets are described as round, white, and marked with 'L;2'.*

FDA Label Image

Lurasidonehclfig1 (Lurasidonehclfig1)

A scatter plot illustrating fold change and 90% confidence intervals in pharmacokinetic parameters (Cmax and AUC) relative to lurasidone alone. The plot compares effects of interacting drugs: strong CYP3A4 inhibitor (Ketoconazole 400 mg/day), moderate CYP3A4 inhibitor (Diltiazem 240 mg/day), strong CYP3A4 inducer (Rifampin 600 mg/day), and Lithium 600 mg BID.*

FDA Label Image

Lurasidonehclfig2 (Lurasidonehclfig2)

A scatter plot with horizontal error bars showing fold change and 90% confidence intervals for various interacting drugs compared to each drug alone. The x-axis represents change relative to interactive drug alone from -1.0 to 1.0. Drugs include Digoxin, Midazolam, Ethinyl Estradiol, Norelgestromin, and Lithium at specified doses. Each drug's pharmacokinetic parameters like Cmax, AUC, or Ctrough are plotted.*

FDA Label Image

Lurasidonehclfig3 (Lurasidonehclfig3)

A forest plot showing fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of Lurasidone Hydrochloride related to renal impairment (mild, moderate, severe), hepatic impairment (mild, moderate, severe), and population factors (gender and race). The x-axis is labeled as 'Change relative to reference' with values ranging from 0 to 6. A note indicates the Asian race data is compared to Caucasian.*

FDA Label Image

Lurasidonehclstructure (Lurasidonehclstructure)

Chemical structure of Lurasidone Hydrochloride, showing its molecular arrangement with aromatic rings, nitrogen, sulfur atoms, and hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.